Skip to main content
. 2022 Aug 24;74(6):1279–1285. doi: 10.1007/s43440-022-00408-6

Fig. 1.

Fig. 1

Ordinal scale categories at consecutive time points in all patients with SpO2 ≤ 95% treated with molnupiravir (MOL) within 5 days of symptom onset or no antiviral treatment (NO AVT); the bar sections represent the proportions of the ordinal scale categories